ABSTRACT
Ravuconazole belongs to a group of “second-generation” triazoles and was developed to overcome limitations of other azoles including drug resistance and drug interactions (Maertens, 2004; Pasqualotto and Denning, 2008). Formerly BMS-207147 and ER-30346, it was discovered by Eisai Co. Ltd. in Japan, developed by Bristol-Myers Squibb, and is now held again by Eisai. It is structurally related to fluconazole and voriconazole (Fung-Tomc et al., 1998), but like isavuconazole, has a long half-life (Pasqualotto and Denning, 2008). Its chemical structure is shown in Figure 160.1. Chemical structure of ravuconazole. https://s3-euw1-ap-pe-df-pch-content-public-p.s3.eu-west-1.amazonaws.com/9781315152110/08d8042d-9481-4a8d-8c27-9bd589f6de6b/content/fig160_1.tif" xmlns:xlink="https://www.w3.org/1999/xlink"/>
